Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones
June 12, 202615 min
Show notes
In this episode of “The Top Line,” recorded on site at Fierce Biotech Week in Boston, Fierce’s Ayla Ellison sits down with Christelle Huguet, Ph.D., executive vice president and head of R&D at Ipsen, to discuss how the company is building its pipeline through external innovation while maintaining internal scientific accountability. Huguet explains Ipsen’s approach to partnering, describing the company as an “accelerator” that helps move promising science from academic labs and biotech partners toward patients. She also discusses how Ipsen evaluates which programs move forward, why transparency with partners is essential from the start and what the company is watching as it heads into a year with several key clinical and regulatory milestones. To learn more about the topics in this episode: Ipsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3 Ipsen scuttles liver disease candidates from $952M Albireo acquisition See omnystudio.com/listener for privacy information.
Transcript
Transcript not available for this episode yet.
More from The Top Line
Behind the headlines of ASCO 2026
Jun 5, 202629 min
Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)
Jun 3, 202621 min
Boston, China and the future of biotech
May 29, 202635 min
Why direct-to-patient is the future of pharma access (Sponsored)
May 28, 20269 min
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
May 22, 202612 min